Estradiol vaginal - TherapeuticsMD

Drug Profile

Estradiol vaginal - TherapeuticsMD

Alternative Names: Estradiol VagiCap™; TX- 12-004-HR; TX-004HR; VagiCap; Yuvvexy

Latest Information Update: 17 Mar 2017

Price : $50

At a glance

  • Originator TherapeuticsMD
  • Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Hormones; Pregnenediones; Small molecules
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Atrophic vaginitis

Most Recent Events

  • 28 Feb 2017 TherapeuticsMD has patents pending for Estradiol vaginal in Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea (TherapeuticsMD 10-K, February 2017)
  • 19 Sep 2016 FDA assigns PDUFA action date of 07/05/2017 for estradiol vaginal for Atrophic vaginitis
  • 19 Sep 2016 The US FDA accepts NDA for estradiol vaginal for Atrophic vaginitis for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top